|Defined daily dose||40 units|
|Bioavailability||60% (when administered s.c.)|
|Elimination half-life||5–7 hours|
|Chemical and physical data|
|Molar mass||5916.89 g·mol−1|
|(what is this?)|
Insulin detemir, sold under the brand name Levemir among others, is a long-acting insulin used to treat both type 1 and type 2 diabetes. It is used by injection under the skin. It is effective for up to 24 hours.
Common side effects include low blood sugar, allergic reactions, pain at the site of injection, and weight gain. Use in pregnancy and breastfeeding appears safe. It works by increasing the amount of glucose that tissues take in and decreasing the amount of glucose made by the liver.
Insulin detemir was approved for medical use in the European Union in June 2004 and in the United States in June 2005. In the United Kingdom it costs the NHS about £2.80 per 100 units as of 2019. In the United States the wholesale cost of this amount is about US$29.50. In 2017, it was the 114th most commonly prescribed medication in the United States, with more than six million prescriptions.
It is an insulin analogue in which a fatty acid (myristic acid) is bound to the lysine amino acid at position B29. It is quickly absorbed after which it binds to albumin in the blood through its fatty acid at position B29. It then slowly dissociates from this complex.
Society and culture
On June 13, 2009, the U.S. Food and Drug Administration (FDA) issued a public health advisory for insulin determir after learning that 129,000 stolen vials reappeared and were being sold in the U.S. market. The FDA warned that the stolen vials "may not have been stored and handled properly and may be dangerous for patients to use." The stolen vials were identified as lots XZF0036, XZF0037, and XZF0038.
- "Insulin detemir (Levemir) Use During Pregnancy". Drugs.com. 12 June 2019. Retrieved 14 April 2020.
- "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 6 September 2020.
- "Levemir FlexPen 100 units/ml solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC)". (emc). 21 May 2018. Retrieved 14 April 2020.
- "Levemir InnoLet 100 units/ml solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC)". (emc). 21 May 2018. Retrieved 14 April 2020.
- "Levemir Penfill 100 units/ml solution for injection in cartridge - Summary of Product Characteristics (SmPC)". (emc). 21 May 2018. Retrieved 14 April 2020.
- "Insulin Detemir Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
- "Levemir EPAR". European Medicines Agency (EMA). Retrieved 14 April 2020.
- "Drug Approval Package: Levemir Insulin Detemir[rDNA origin] Injection; NDA #021536". U.S. Food and Drug Administration (FDA). 26 July 2005. Retrieved 14 April 2020.
- British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 701. ISBN 9780857113382.
- "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
- "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
- "Insulin Detemir - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.
- "FDA Issues Public Health Advisory Regarding Levemir Insulin". 13 June 2009. Archived from the original on 17 June 2009. Retrieved 9 March 2019.
- "Insulin detemir". Drug Information Portal. U.S. National Library of Medicine.